Company to join research venture with Oxford
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BRITISH Bio-technology is establishing a joint laboratory with Oxford University for research into new ways of treating viral diseases and cancer, writes Mary Fagan.
The company, which will invest pounds 1.8m in the laboratory over five years, will have worldwide rights to develop and market products.
The venture follows earlier collaborative work between the company and the university leading to the development of an Aids vaccine which has been approved for trials in the UK.
Under the latest agreement the laboratory will target vaccines for viruses including chicken pox, shingles, herpes and hepatitis. The aim is to engineer a completely safe version of the natural virus which could be used to create immunity in patients.
Similar technology will be used to develop ways of stimulating an immune response to proteins which exist on cancer cells.
Keith McCullagh, chief executive of British Bio-technology, said the joint venture would channel basic research at Oxford into usable products.
The company, which has yet to make a profit, said in July that its research and development budget would increase from pounds 11.5m in 1991 to pounds 15m this year to provide for better revenue flows later.
Dr Alan Kingsman, director of the new Collaborative Laboratory and university lecturer in biochemistry, said: 'Our previous work has led to a potentially successful treatment for Aids.
'Now the work of the laboratory will extend the applications to new areas and new diseases.'
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments